Analysts Set Expectations for Processa Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:PCSA)

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for Processa Pharmaceuticals in a note issued to investors on Thursday, April 25th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($1.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Processa Pharmaceuticals’ current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.90) EPS, Q3 2024 earnings at ($0.99) EPS, Q4 2024 earnings at ($0.84) EPS, FY2024 earnings at ($3.82) EPS and FY2025 earnings at ($1.89) EPS.

Separately, Benchmark reissued a “speculative buy” rating on shares of Processa Pharmaceuticals in a report on Wednesday, March 6th.

Processa Pharmaceuticals Trading Up 3.8 %

NASDAQ:PCSA opened at $2.18 on Monday. Processa Pharmaceuticals has a 12 month low of $1.40 and a 12 month high of $18.00. The firm has a fifty day simple moving average of $2.18 and a 200-day simple moving average of $5.53. The company has a market capitalization of $6.23 million, a P/E ratio of -0.29 and a beta of 0.53.

Processa Pharmaceuticals (NASDAQ:PCSA) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.24) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Processa Pharmaceuticals stock. Spinnaker Trust acquired a new stake in Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 76,865 shares of the company’s stock, valued at approximately $26,000. Spinnaker Trust owned approximately 6.25% of Processa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 91.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider David Young acquired 21,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was bought at an average price of $2.45 per share, with a total value of $51,450.00. Following the completion of the acquisition, the insider now owns 79,387 shares of the company’s stock, valued at $194,498.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.20% of the stock is currently owned by corporate insiders.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.